🕵️ Acrivon Therapeutics, Inc. ($ACRV)
SEC insider & ownership activity, last 12 months · CIK 1781174 · every row links its SEC filing
Over the last 12 months insiders sold $1K against $114K of open-market buying. Blume-Jensen Peter bought $82K in discretionary trades (Jan). RA Capital Management, L.P. added 21.6% → 28.8%; Peter Kolchinsky added 21.6% → 28.8%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
3 buyers, $114K (3 lots) · 1 seller, $1K (1 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Blume-Jensen Peter | 1 | $82K | 0 | – | Jan 14, 2026 |
| Devroe Eric | 1 | $17K | 0 | – | Jan 13, 2026 |
| Adam D. Levy | 1 | $15K | 0 | – | Jan 14, 2026 |
| Miller Mary | 0 | – | 1 | $1K | Jul 21, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 28.8% | 13D | Apr 22, 2026 | filing ↗ | |
| Peter Kolchinsky | 28.8% | 13D | Apr 22, 2026 | filing ↗ | |
| Rajeev Shah | 28.8% | 13D | Apr 22, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 27.7% | 13D | Apr 22, 2026 | filing ↗ | |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | 13G | Aug 13, 2025 | filing ↗ | |
| Sands Capital Alternatives, LLC | 6.8% | 13G | Aug 13, 2025 | filing ↗ | |
| Frank M. Sands | 6.8% | 13G | Aug 13, 2025 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jun 17, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 17, 2026 | filing ↗ |
| Earnings (2.02) | May 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 13, 2026 | filing ↗ |
| Earnings (2.02) | Mar 19, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 19, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 19, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 27, 2026 | filing ↗ |
| Agreement terminated (1.02) | Feb 25, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 8, 2026 | filing ↗ |
| Earnings (2.02) | Jan 8, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 8, 2026 | filing ↗ |
| Other events (8.01) | Jan 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 8, 2026 | filing ↗ |
| Earnings (2.02) | Nov 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 13, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 5, 2025 | filing ↗ |
| Earnings (2.02) | Aug 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 13, 2025 | filing ↗ |